The overexpression of p95HER2 and the overexpression of cell surface mucin 4 (MUC4) on breast cancer cells may affect the HER2 target and hinder the binding of trastuzumab to HER2, which is related to poor drug efficacy [41,42]. The gene discussed is ERBB2; the disease is breast carcinoma.